Search peptides, terms, sources/
Research source · 2024

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

About this source

Kind
Research
Design
Human clinical trial
Population
10 people with Barth syndrome entered the extension; 8 reached week 168
Sample size
10
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Open-label extension with no concurrent control group, very small, with 2 participants lost by week 168. Several authors are affiliated with Stealth BioTherapeutics, the developer. Abstract read via Europe PMC; full text not read.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.